Litigation Details for Cytiva Sweden AB v. Bio-Rad Laboratories, Inc. (D. Del. 2018)

Cytiva Sweden AB v. Bio-Rad Laboratories, Inc. (D. Del. 2018)

Docket		Date Filed	2018-11-30
Court	District Court, D. Delaware	Date Terminated	2022-06-30
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Patents	8,022,054
Link to Docket	External link to docket

Details for Cytiva Sweden AB v. Bio-Rad Laboratories, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-30				External link to document

Litigation Summary and Analysis: Cytiva Sweden AB v. Bio-Rad Laboratories, Inc., 1:18-cv-01899

Last updated: February 9, 2026

Case Overview

Cytiva Sweden AB filed a patent infringement suit against Bio-Rad Laboratories, Inc. in the United States District Court for the District of Delaware. The case number is 1:18-cv-01899. The dispute centers on allegations that Bio-Rad infringed patents related to chromatography hardware and methods used in bioprocessing applications.

Key Patents and Claims

Cytiva asserted that Bio-Rad infringed U.S. Patent Nos. 9,674,362 and 10,077,959. The patents cover innovations in filtration and chromatography devices, particularly focusing on methods for optimizing flow rates and reducing dead volume in chromatography columns.

The patents claim:

• Specific structural features of chromatography columns, including novel connector mechanisms.
• Methods for maintaining flow uniformity during column operation.
• Techniques for reducing sample hold-up and improving separation efficiency.

Timeline and Procedural Developments

• Filing (2018): Cytiva initiated litigation alleging direct infringement by Bio-Rad.
• Initial Motions: Bio-Rad moved to dismiss or challenge patent validity, citing prior art.
• Discovery Phase (2019-2020): Both parties exchanged documents, conducted depositions, and filed preliminary motions.
• Summary Judgment (2021): Cytiva sought to establish infringement and validity, while Bio-Rad challenged certain claims as invalid or non-infringing.
• Trial Date: Not yet scheduled as of the latest available filings.

Legal Arguments

Cytiva’s Position:

• The products supplied by Bio-Rad incorporate elements that infringe asserted claims.
• The patents are valid, novel, and non-obvious, supported by prior art searches and expert testimony.

Bio-Rad’s Defense:

• The patents are invalid due to prior art references suggesting similar features before the patent dates.

• The accused products do not infringe because they lack certain structural features or operate through different methods.

• The company further argues that Cytiva’s patents are overly broad and cover obvious modifications.

Patent Validity Challenges

Bio-Rad contested the validity of the patents based on art references such as:

• Prior publications describing similar chromatography column connectors.
• Earlier devices in the bioprocess industry with comparable flow optimization features.
• Arguments suggesting the patents are an obvious extension of existing technology.

The validity issues are central to the case, with potential invalidity undermining Cytiva’s infringement claims.

Infringement and Technical Disputes

The infringement analysis involves:

• A claim construction review, focusing on structural language in the patents.
• Technical comparison of Bio-Rad’s product specifications against patent claims.
• Expert testimonies on whether features like the connector mechanism and flow channels effectively replicate patented inventions.

Potential Outcomes

• A court ruling that Bio-Rad’s products infringe the patent rights, leading to injunctive relief and damages.
• A finding that the patents are invalid, which would eliminate Cytiva’s claims and potentially open the market further for Bio-Rad.
• A settlement or licensing agreement before trial.

Market and Business Impacts

The case impacts the bioprocessing equipment market by shaping the patent landscape. Cytiva’s enforcement aligns with efforts to protect core innovations, whereas invalidity or non-infringement findings could enable Bio-Rad to expand product offerings without patent encumbrances.

Recent Status and Next Steps

As of the latest filings in early 2023:

• Both parties continue to litigate validity issues.
• No trial date has been announced.
• Discovery remains ongoing, with expert reports due soon.

Key Takeaways

• The case illustrates typical patent litigation tactics, including validity challenges and technical comparisons.
• The core issue hinges on structural infringement and prior art considerations.
• Outcomes can substantially influence product designs and market share in chromatography and bioprocessing.

FAQs

1. Which patents are involved in the Cytiva vs. Bio-Rad case?

   U.S. Patent Nos. 9,674,362 and 10,077,959.

2. What is the main technical issue?

   Whether Bio-Rad’s products infringe on Cytiva’s patents related to chromatography column connectors and flow methods.

3. What are the primary defenses raised by Bio-Rad?

   Patent invalidity due to prior art and non-infringement owing to structural differences.

4. How could invalidity claims affect the case?

   If courts find the patents invalid, Cytiva’s infringement claims fall, and Bio-Rad can operate without licensing concerns.

5. When might a resolution be expected?

   Court proceedings are ongoing, with no scheduled trial date as of early 2023.

---

Sources

[1] Court filings and docket reports from U.S. District Court for the District of Delaware.